Navicixizumab Earns FDA Fast Track Designation for Heavily Pretreated Ovarian Cancer
News
The U.S. Food and Drug Administration (FDA) has granted fast track designation to navicixizumab (OMP-305B83) as a potential therapy for heavily pretreated ovarian cancer, Mereo BioPharma, the therapy’s developer, announced. Fast track ... Read more